Published in J Immunol on June 15, 1995
Activation of bovine lymphocyte subpopulations by staphylococcal enterotoxin C. Infect Immun (1998) 1.09
Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin Diagn Lab Immunol (2001) 1.00
Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am J Pathol (1997) 0.98
Superantigen activation of CD4+ and CD8+T cells from HIV-infected subjects: role of costimulatory molecules and antigen-presenting cells (APC) Clin Exp Immunol (1998) 0.95
T cell- and perforin-dependent depletion of B cells in vivo by staphylococcal enterotoxin A. Immunology (1998) 0.83
A mutation of F47 to A in staphylococcus enterotoxin A activates the T-cell receptor Vbeta repertoire in vivo. Infect Immun (1997) 0.79
ICAM-1 costimulation induces IL-2 but inhibits IL-10 production in superantigen-activated human CD4+ T cells. Immunology (1998) 0.78
Induction of selective anergy by toxic shock syndrome toxin-1 in CD8+ T cells. Immunology (1997) 0.75
Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen. PLoS One (2014) 0.75
[Malignant skin melanoma a difficult clinical diagnosis. The primary management is often insufficient]. Lakartidningen (1997) 3.97
Binding of staphylococcal enterotoxin A to HLA-DR on B cell lines. J Immunol (1989) 2.32
Crystal structure of the superantigen staphylococcal enterotoxin type A. EMBO J (1995) 1.99
Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst (1997) 1.91
Cerebellar leukoencephalopathy: most likely histiocytosis-related. Neurology (2008) 1.73
Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med (1994) 1.66
Similar frequencies and kinetics of cytokine producing cells in murine peripheral blood and spleen. Cytokine detection by immunoassay and intracellular immunostaining. J Immunol Methods (1993) 1.60
Histamine in endocrine cells in the stomach. A survey of several species using a panel of histamine antibodies. Histochemistry (1986) 1.57
Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J (1995) 1.54
Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells. J Immunol (1990) 1.51
Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol (1996) 1.51
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. Br J Dermatol (2013) 1.49
Long-term effects of neonatal estrogen treatment on mitogen responsiveness of mouse spleen lymphocytes. J Natl Cancer Inst (1979) 1.49
Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients. Eur J Cancer (1994) 1.49
Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol (1993) 1.48
Trends in cutaneous malignant melanoma in Sweden 1997-2011: thinner tumours and improved survival among men. Br J Dermatol (2015) 1.43
Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci U S A (1994) 1.38
Two subsets of human CD4+ T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies. Eur J Immunol (1988) 1.35
Neuroradiographic findings in the newborn period and long-term outcome in children with symptomatic congenital cytomegalovirus infection. Pediatrics (1997) 1.33
Cross-linking of major histocompatibility complex class II molecules by staphylococcal enterotoxin A superantigen is a requirement for inflammatory cytokine gene expression. J Exp Med (1995) 1.30
Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J Immunol (1998) 1.30
A recombinant C-terminal fragment of staphylococcal enterotoxin A binds to human MHC class II products but does not activate T cells. J Immunol (1991) 1.29
Immunoregulatory role of IL-10 during superantigen-induced hyporesponsiveness in vivo. J Immunol (1997) 1.29
The crystal structure of staphylococcal enterotoxin type D reveals Zn2+-mediated homodimerization. EMBO J (1996) 1.23
Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc Natl Acad Sci U S A (1991) 1.22
In vivo anergized CD4+ T cells express perturbed AP-1 and NF-kappa B transcription factors. Proc Natl Acad Sci U S A (1996) 1.21
Stimulation of human naive and memory T helper cells with bacterial superantigen. Naive CD4+45RA+ T cells require a costimulatory signal mediated through the LFA-1/ICAM-1 pathway. J Immunol (1992) 1.17
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer (2004) 1.17
Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer (2001) 1.15
Characterization of individual tumor necrosis factor alpha-and beta-producing cells after polyclonal T cell activation. J Immunol Methods (1989) 1.14
Immunopharmacology of the superantigen staphylococcal enterotoxin A in T-cell receptor V beta 3 transgenic mice. Immunology (1993) 1.13
Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells. J Immunol (1987) 1.13
Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int J Cancer (1993) 1.11
Superantigens anergize cytokine production but not cytotoxicity in vivo. Immunology (1994) 1.10
Human major histocompatibility complex class II-negative colon carcinoma cells present staphylococcal superantigens to cytotoxic T lymphocytes: evidence for a novel enterotoxin receptor. Eur J Immunol (1991) 1.09
Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Prostate (2004) 1.08
T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol (1995) 1.07
Cisplatin induces the proapoptotic conformation of Bak in a deltaMEKK1-dependent manner. Mol Cell Biol (2001) 1.07
Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol (1985) 1.06
CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res (2000) 1.05
Antibody-targeted superantigen therapy induces tumor-infiltrating lymphocytes, excessive cytokine production, and apoptosis in human colon carcinoma. Eur J Immunol (1996) 1.05
Expression of class Pi glutathione transferase in human malignant melanoma cells. Carcinogenesis (1987) 1.05
Induction of interleukin-1 in human monocytes by the superantigen staphylococcal enterotoxin A requires the participation of T cells. Cell Immunol (1991) 1.05
Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. J Immunol (2000) 1.04
Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. J Natl Cancer Inst (2010) 1.04
Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo. Proc Natl Acad Sci U S A (1995) 1.03
Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology (1990) 1.03
Superantigen-based tumor therapy: in vivo activation of cytotoxic T cells. Cancer Immunol Immunother (1993) 1.03
Superantigen-based immunotherapy: a phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin A recombinant fusion protein, in advanced pancreatic and colorectal cancer. J Clin Oncol (1997) 1.02
Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue. Neuropharmacology (2002) 1.02
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer (2003) 1.01
Flow cytofluorometric DNA analyses of metastases of human malignant melanomas. Anal Quant Cytol (1982) 1.01
Staphylococcal-enterotoxin-dependent cell-mediated cytotoxicity. Immunol Today (1991) 1.01
Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Acad Sci U S A (1993) 1.00
Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol (2001) 1.00
Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother (1995) 0.99
Fusion of a signal sequence to the interleukin-1 beta gene directs the protein from cytoplasmic accumulation to extracellular release. Cell Immunol (1996) 0.99
Phenotypical and functional differentiation of CD4+ CD45RA+ human T cells following polyclonal activation. Scand J Immunol (1990) 0.98
Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses. Am J Pathol (1997) 0.98
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer (2003) 0.97
Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur J Immunol (1993) 0.95
Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma. Cancer Res (1986) 0.95
p53 mutations in urinary bladder cancer. Br J Cancer (2001) 0.95
Histamine inhibits interleukin 1 production by lipopolysaccharide-stimulated human peripheral blood monocytes. Scand J Immunol (1988) 0.95